ARIMIDEX® - is used in addition to other treatments for breast cancer. Specifically it is used for hormone receptor-positive breast cancer. It has also been used to prevent breast cancer in those at high risk. Anastrozole was patented in 1987 and was approved for medical use in 1995. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.
- Treat Breat Cancer.
- Peripheral Precocious Puberty.
- Increases Testosterone Levels in Males.
- Treat Hypogonadism.
GUARANTEE & EXPIRY DATE
100% original from US/UK AstraZeneca Pharmaceuticals. This is not a generic.
All packs are air tight sealed and expire up to 06.2024.
Photos of the product are for illustation purpose only and may vary according to the manufacturer.
Anastrozole is used in the treatment and prevention of breast cancer in women. Arimidex® and Tamoxifen Alone or in Combination (ATAC) trial was of localized breast cancer and women received either anastrozole, the selective estrogen receptor modulator tamoxifen, or both for five years, followed by five years of follow-up. After more than 5 years the group that received anastrozole had better results than the tamoxifen group. The trial suggested that anastrozole is the preferred medical therapy for postmenopausal women with localized estrogen receptor-positive breast cancer.
ARIMIDEX® comes in the form of tablets for oral use: 1 mg per tablet, 28 tablets per pack.
Anastrazole - 1 mg.
Lactose monohydrate - 93 mg, povidone - 2 mg, sodium carboxymethyl starch - 3 mg, magnesium stearate - 1 mg.
Film layer of the tablet: hypromellose - 1.50 mg, macrogol 300 - 0.30 mg, titanium dioxide - 0.45 mg.
Orally with water. It is recommended to take the drug at the same time each day.
Adults, including the elderly: 1 mg once per 24 hours. If signs of disease progression appear, the drug should be discontinued.
As adjuvant therapy, the recommended treatment duration is 5 years.
Renal dysfunction: dose adjustment in patients with mild to moderate renal impairment is not required.
Impaired liver function: dose adjustment in patients with a mild degree of impaired liver function is not required.
A single dose of Arimidex, which could lead to life-threatening symptoms has not been established. There is no specific antidote; in case of an overdose, treatment should be symptomatic. You can induce vomiting if the patient is conscious. Dialysis may be performed. General supportive therapy, patient monitoring, and monitoring the function of vital organs and systems are recommended.
The frequency of occurrence was calculated from the number of adverse events observed in the III phase of the study in 9366 postmenopausal women with operable breast cancer treated for 5 years, while the frequency of adverse events in the comparison groups and the opinion of the researcher regarding the dependence of the adverse event on the subject drug not considered.
Determination of the frequency of adverse reactions: very often (more than or equal to 10%); often (from 1 to less than 10%); infrequently (from 0.1 to less than 1%); rarely (from 0.01 to less than 0.1%); very rarely (less than 0.01%)
Musculoskeletal and connective tissue: very often - arthralgia / stiffness of joints, arthritis, often - bone pain, myalgia, infrequently - trigger finger.
Genitals and mammary gland: often - dryness of the vaginal mucosa; vaginal bleeding (mainly during the first weeks after cancellation or change of previous hormone therapy to Arimidex®).
Skin and subcutaneous tissues: very often - a skin rash, often - thinning of the hair (alopecia), allergic reactions, rarely - urticaria, rarely - erythema multiforme, anaphylactoid reaction, skin vasculitis (including some cases of purpura (Shenlein-Genoch syndrome)) , very rarely - Stevens-Johnson syndrome, angioedema.
Gastrointestinal tract: very often - nausea, often - diarrhea, vomiting.
Liver and biliary tract: often - increased activity of alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, infrequently - increased activity of gamma-glutamyl transferase and bilirubin concentration, hepatitis.
Nervous system: very often - headache, often drowsiness, carpal tunnel syndrome (mainly observed in patients with risk factors for this disease), sensitivity disorders (including paresthesia, loss or distortion of taste sensations).
Metabolism and nutrition: often - anorexia, hypercholesterolemia, infrequently - hypercalcemia (with / without increasing the concentration of parathyroid hormone). Taking the drug may cause a decrease in bone mineral density due to a decrease in the concentration of circulating estradiol, thereby increasing the risk of osteoporosis and bone fractures.
General disorders: very often - asthenia of mild or moderate severity.
Adverse events noted during clinical trials that are not related to the use of Arimidex: anemia, constipation, dyspepsia, back pain, abdominal pain, increased blood pressure, increased body weight, depression, insomnia, dizziness, anxiety, paresthesia.
Store in dry place at room temperature. Do not exceed storage temperature higher than 25 degrees Celcius. Keep away from direct sunlight. Keep locked and away from children.
Ask us any questions about ARIMIDEX®.